Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline Buys Back 1.3 Million Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 06:28pm CET

GlaxoSmithKline PLC (>> GlaxoSmithKline plc) said Friday it has purchased 1,300,000 ordinary shares to be held in treasury.

MAIN FACTS:

-Highest price paid: 1455 pence per share.

-Lowest price paid: 1425 pence per share.

-Shares at 1610 GMT down 1%, at 1427 pence, valuing the company at GBP72 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc, GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
01/15 GLAXOSMITHKLINE : National Institutes of Health - Brian Berridge tapped to manag..
01/13 GLAXOSMITHKLINE : Brian Berridge Tapped to Manage National Toxicology Program
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/11 GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Target Antimalarial Agent..
01/11 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Have Provided New Data on Chr..
01/11 GLAXOSMITHKLINE : New Drug Targets Data Have Been Reported by Investigators at G..
01/11 GLAXOSMITHKLINE : Study Results from GlaxoSmithKline plc Update Understanding of..
01/11 NEW PHARMACOLOGY STUDY FINDINGS HAVE : A...
01/10 BioCentury - GSK confirms management overhaul
01/09 GLAXOSMITHKLINE : GSK CEO says looking at Pfizer consumer business, but not a pr..
More news
News from SeekingAlpha
01:29p STOCKS FOR 2018 : Beaten Down, With Dividends, And Recession Resistant
11:35a FDA launches new program to boost transparency of clinical data used to suppo..
08:54a 2018 STRATEGIC OUTLOOK : Will Fortune Favor The Bold In Biotech?
07:11a WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
Financials ( GBP)
Sales 2017 30 078 M
EBIT 2017 8 303 M
Net income 2017 3 592 M
Debt 2017 13 830 M
Yield 2017 5,91%
P/E ratio 2017 19,27
P/E ratio 2018 15,29
EV / Sales 2017 2,69x
EV / Sales 2018 2,65x
Capitalization 67 080 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 15,5  GBP
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE2.31%92 553
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987